Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome (AAS-Lynch)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02813824 |
Recruitment Status :
Recruiting
First Posted : June 27, 2016
Last Update Posted : October 26, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lynch Syndrome | Drug: Acetylsalicylic acid lysinate 300 mg Drug: Placebo (for Aspirin 300) Drug: Acetylsalicylic acid lysinate 100 mg Drug: Placebo 100 (for Aspirin 100) | Phase 3 |
Lynch syndrome (LS) is the most common inherited colorectal cancer syndrome, and results from germline mutations in mismatch repair genes that confer a high lifetime risk of colorectal cancer (CRC) (60 to 70%). Most CRCs arise from asymptomatic polyps. Development of such polyps into cancer can be prevented if polyps are detected early by endoscopy and removed. Colonoscopy is proposed every 2 years in LS patients more than 25 years old, and every year when colonic neoplasia has been detected. Efficient chemoprevention has the potential to represent a cost-effective intervention in these patients and could allow a delay in colonoscopic surveillance.
Several epidemiological studies have shown that regular use of low dose aspirin (75 to 300 mg/d) is associated with a 20 to 30 % reduction in the risk of sporadic colonic polyps and CRC. Four randomised controlled trials (RCT) have also shown a decrease in colorectal polyp recurrence. In a pooled analysis of cardio-vascular prevention RCTs, as well as in a meta-analysis, daily aspirin was associated with a reduced risk of CRC and CRC associated mortality. Aspirin preventive benefit is expected to outweigh its putative side effects in high risk patients. The CAPP2 study in Lynch syndrome patients showed that aspirin (300 mg x2/d) did not reduce significantly the risk of colorectal neoplasia after 29 months, but an extended follow-up (mean 56 months) showed a reduction in colorectal cancer in the aspirin group. In this study, the endoscopic follow-up was not optimal with a relatively low detection rate of colorectal neoplasia according to usual reported rate when chromo-endoscopy is performed. So, the real effect and clinical benefit of aspirin are still to be characterised in Lynch syndrome patients.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 852 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Assessment of the Effect of a Daily Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome |
Actual Study Start Date : | November 14, 2017 |
Estimated Primary Completion Date : | November 15, 2024 |
Estimated Study Completion Date : | December 15, 2025 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Aspirin300
Acetylsalicylic acid 300 mg tablet by mouth, daily dose during 4 years
|
Drug: Acetylsalicylic acid lysinate 300 mg
Daily dose during 4 years
Other Name: Aspirin300 |
Placebo Comparator: Placebo300
Placebo (like Acetylsalicylic acid 300 mg) tablet by mouth, daily dose during 4 years
|
Drug: Placebo (for Aspirin 300)
Daily dose during 4 years
Other Name: Placebo300 |
Active Comparator: Aspirin100
Acetylsalicylic acid 100 mg tablet by mouth, daily dose during 4 years
|
Drug: Acetylsalicylic acid lysinate 100 mg
Daily dose during 4 years
Other Name: Aspirin100 |
Placebo Comparator: Placebo100
Placebo (like Acetylsalicylic acid 100 mg) tablet by mouth, daily dose during 4 years
|
Drug: Placebo 100 (for Aspirin 100)
Daily dose during 4 years
Other Name: Placebo100 |
- Number of patients with at least one adenoma seen on chromo-endoscopy 48 months after complete withdrawal of polyps and initiation of treatment (aspirin or placebo) [ Time Frame: 4 years ]To look for a preventive effect of low-dose aspirin (100 or 300 mg/d) compared with placebo on new or recurrent colorectal adenomas in patients with Lynch syndrome
- Delay between the onset of 1 adenoma after complete resection of polyps and date of start of treatment (aspirin vs placebo) [ Time Frame: 24 and 48 months ]
- Number of patients who presented an adenoma during follow-up based on the gene reached (MLH1, MSH2, MSH6, PMS2, or without other identified anomalies) [ Time Frame: 24 and 48 months ]
- Load serrated polyps after 24 and 48 months of treatment [ Time Frame: 24 and 48 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient with Lynch syndrome bearing an alteration of "mismatch repair" genes or,when no characteristic alteration has been found, with a personal or family history of Lynch syndrome according to modified Amsterdam criteria
- Aged more than 25 years, et aged more than 18 years with an early familial history and any reason to perform a colonoscopy every 2 years
- Aged less than 75 years
Exclusion Criteria:
- Known allergy to aspirin (including a history of asthma induced by the administration of salicylates or substances with similar activity, including non-steroidal anti-inflammatory)
- Need for a prolonged treatment (prevention of cardio-vascular risk) or repeated treatments (recurring migraines) using aspirin or another non-steroidal anti-inflammatory drug (NSAID)
- Pregnancy or breast feeding
- Participation to another clinical trial during the 12 weeks before inclusion

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02813824
Contact: Zahia BEN ABDESSELAM | 33148957435 | zahia.ben-abdesselam@aphp.fr |
France | |
Hôpital Avicenne | Recruiting |
Bobigny, France, 93000 | |
Contact: Robert BENAMOUZIG, Pr robert.benamouzig@aphp.fr | |
Contact: Amal BOURKEB amal.bourkeb@aphp.fr |
Principal Investigator: | Robert BENAMOUZIG, Pr | Assistance Publique - Hôpitaux de Paris |
Responsible Party: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT02813824 |
Other Study ID Numbers: |
P130937 |
First Posted: | June 27, 2016 Key Record Dates |
Last Update Posted: | October 26, 2020 |
Last Verified: | October 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Adenoma Colorectal Neoplasms, Hereditary Nonpolyposis Syndrome Disease Pathologic Processes Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplastic Syndromes, Hereditary Digestive System Diseases |
Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Genetic Diseases, Inborn DNA Repair-Deficiency Disorders Metabolic Diseases Aspirin Acetylsalicylic acid lysinate Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents |